Anti Influenza Virus Activity of Amantadine, Rimantadine and Analogues

  • J. S. Oxford
Part of the NATO ASI Series book series (NSSA, volume 73)


Two decades have passed since the initial discovery of the antiviral effect of the primary amine amantadinel. During this period extensive controlled clinical trials in more than 20,000 volunteers have established an unequivocal prophylactic effect against influenza A virus infection appr ximately equivalent to that of inactivated influenza vaccines2–6. In addition a mild therapeutic effect has been demonstrated against H2N2, H3N2 and H1N1 viruses5. Earlier fears that new influenza virus antigenic variants which constantly emerge and assume epidemiological significance would be less inhibited by amantadine have not been fulfilled. Recent field viruses (at least strains isolated up to 1981) are as well inhibited in vitro and in the clinic as the first H2N2 viruses tested in the early 60’s. Recently there has been more interest in finding ways of using the compound usefully on a large scale. This fresh approach has probably been stimulated by the continued absence of any more effective influenza inhibitors and also by the heightened interest in antiviral compounds in general, following the increasingly successful use in the clinic of three new anti-herpes compounds, acyclovir, phosphonoformate and bromovinyl deoxyuridine7,8.


Influenza Virus Antiviral Activity Influenza Vaccine H3N2 Virus Antiviral Compound 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    W.L. Davies, R.R. Grunert, R.F. Haff, J.W. McGahen, E.M. Neumayer, M. Paulshock, J.C. Watts, T.R. Wood, E.C. Hermann and C.E. Hoffman, Antiviral activity of 1-adamantanamine. Science 144: 862 (1964)PubMedCrossRefGoogle Scholar
  2. 2.
    J.S. Oxford and A. Galbraith, Antiviral activity of amantadine: a review of laboratory and clinical data. Pharmacology and Therapeutics 11: 181 (1980)PubMedCrossRefGoogle Scholar
  3. 3.
    C.H. Stuart Harris, J.S. Oxford, Eds “Problems in Antiviral Therapy’ Academic Press, London In pressGoogle Scholar
  4. 4.
    M.K. Indulen, V.A. Kalninya, Studies of the antiviral effect and the mode of action of the anti-influenza compound rimantadine. In: Recent Developments in Antiviral Chemotherapy L.Collier and J.S. Oxford (Eds) Academic Press, London (1980)Google Scholar
  5. 5.
    D.M. Zlydnikov, O.I. Kubar, T.P. Kovaleva and L.E. Kamforin, Study of rimantadine in the USSR: a review of the literature. Reviews of Infectious Diseases 3: 408 (1981)PubMedCrossRefGoogle Scholar
  6. 6.
    J.R. La Montagne and G. J. Galasso Report of a workshop on clinical studies of the efficacy of amantadine and rimantadine against influenza virus J.Infect.Dis. 138: 928 (1978)Google Scholar
  7. 7.
    L. Collier and J.S. Oxford Eds. Developments in Antiviral therapy. Academic Press, London (1980)Google Scholar
  8. 8.
    G.J. Galasso, T.C. Merigan and R.A. Buchanan Eds. Antiviral agents and viral disease of man. Raven Press, New York (1979)Google Scholar
  9. 9.
    M.D. Eaton, I.E. Low, A.R. Scala and S. Uretsky Inhibition by ammonium ion of the growth of influenza virus in chorioallantoic tissue. Virology 18: 102 (1962)Google Scholar
  10. 10.
    J.S. Oxford and G.C. Schild Immunofluorescent studies on the inhibition of influenza A and B in mammalian cell cultures by amantadine. J.Gen.Virol 2: 377 (1968)PubMedCrossRefGoogle Scholar
  11. 11.
    J.S. Oxford, I.S. Logan and C.W. Potter In vivo selection of an influenza A2 strain resistant to amantadine Nature 226: 82 (1970)PubMedCrossRefGoogle Scholar
  12. 12.
    H. Heider, B. Adamczyk, H.W. Presber, C. Schroeder, R. Feldblum and M.K. Indulen Occurrence of amantadine and rimantadine-resistant influenza A virus strains during the 1980 epidemic. Acta Viro 25: 395 (1981)Google Scholar
  13. 13.
    D.L. Swallow. Antiviral agents. Prog. Drues. Res. 22: 267 (1978)Google Scholar
  14. 14.
    J.W. Tilley and M.J. Kramer Amino.adamantane derivatives. Progress in Medicinal Chemistry 18: 1 (1981)CrossRefGoogle Scholar
  15. 15.
    A.P. Kendal, J.M. Joseph, G. Kobayashi, D. Nelson, C.R. Reyes, M.R. Ross, J.L. Sarandría, R. White, D.F. Woodall, G.R. Noble and W.R. Dawdle. Laboratory-based surveillance of influenza virus in the United States during the winter of 1977–78. I.Periods of prevalence of H1N1 and H3N2 influenza strains, their relative rates of isolation in different age groups and detection of antigenic variants. Amer.J.Epidemiol. 110: 449 (1979)Google Scholar
  16. 16.
    J.F. Young, U. Desselberger and P.Palese Evolution of human influenza A viruses in nature: sequential mutations in the genomes of new H1N1 isolates. Cell 18: 73 (1979)PubMedCrossRefGoogle Scholar
  17. 17.
    G. Douglas Amantadine: Should it be used as an antiviral? Controversies in Therapeutics. Publ. W.B. Saunders Co. p271 (1980)Google Scholar
  18. 18.
    R. Dolin, R.C. Reichman, P. Madore, R. Maynard, P.M. Linton, and J. Webber-Jones Controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection New. England J.Med. 307: 580 (1982)CrossRefGoogle Scholar
  19. 19.
    C.H. Stuart-Harris Clinical aspects of the respiratory tract In: Chemoprophylaxis and virus infections of the respiratory tract. Volume 1 p 26 Ed. J.S. Oxford CRC Press Inc. Cleveland, Ohio (1977)Google Scholar
  20. 20.
    C.H. Stuart-Harris The epidemiology and prevention of influenza. American Scientist 69: 166 (1981)PubMedGoogle Scholar
  21. 21.
    C.H. Stuart-Harris and G.C. Schild In: Influenza, the viruses and the disease. Edward Arnold, London,(1976)Google Scholar
  22. 22.
    J. Elliot Consensus on amantadine use in influenza A. J.Amer.Med.Assoc. 242: 2383 (1979)CrossRefGoogle Scholar
  23. 23.
    A.B. Sabin Amantadine hydrochloride: Analysis of data related to its proposed use for prevention of A2 influenza virus disease in human beings. J.Amer.Med.Assoc. 200: 135 (1967)CrossRefGoogle Scholar
  24. 24.
    A.B. Sabin Amantadine and influenza: evaluation of conflicting reports. J.Infect.Dis. 138: 557 (1978)CrossRefGoogle Scholar
  25. 25.
    M.D. Lubeck, J.L. Schulman and P. Palese Susceptibility of influenza A viruses to amantadine is influenced by the gene coding for M protein. J.Virol. 28: 710 (1978)PubMedGoogle Scholar
  26. 26.
    A.J. Hay, N.C.T. Kennedy, J.J. Skehel and G. Appleyard The matrix protein gene determines amantadine sensitivity of influenza viruses. J.Gen.Virol. 42: 189 (1979)PubMedCrossRefGoogle Scholar
  27. 27.
    C. Scholtissek and G.P. Faulkner Amantadine resistant and sensitive influenza A strains and recombinants. J.Gen.Virol. 44: 807 (1979)PubMedCrossRefGoogle Scholar
  28. 28.
    M. Hamzawi, R. Jennings, and C.W. Potter The amantadine sensitivity of recombinant and parental influenza virus strains. Med.Microbiol. and Immunology 169: 259 (1981)CrossRefGoogle Scholar
  29. 29.
    A. Sugiura and M. Ueda Neurovirulence of influenza virus in mice I. Neurovirulence of recombinants between virulent and avirulent virus strains. Virology 101: 440 (1980)PubMedCrossRefGoogle Scholar
  30. 30.
    T. Ogawa and M. Ueda Genes involved in the virulence of an avian influenza virus. Virology 113: 304 (1981)PubMedCrossRefGoogle Scholar
  31. 31.
    Y. Ghendon, A. Klimov, N. Gorodkova and L. Dohner Genome analysis of influenza A virus strains isolated during an epidemic of 1979–1980. J.Gen.Virol. 56: 303 (1981)PubMedCrossRefGoogle Scholar
  32. 32.
    C.E. Hoffman, E.M. Neum4yer, R.F. Haff and R.A. Coldsby Mode of action of the antiviral activity of amantadine in tissue culture. J. Bacteriology 90: 623 (1965)Google Scholar
  33. 33.
    A.G.Bukrinskaya, N.K. Vorkunova and R.A. Narmanbetova Rimantadine hydrochloride blocks the second step of influenza virus uncoating Arch.Virol 66: 275 (1980)CrossRefGoogle Scholar
  34. 34.
    I.A. Wilson, J.J. Skehel and D.C. Wiley Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3R resolution. Nature 289: 366 (1981)PubMedCrossRefGoogle Scholar
  35. 35.
    J.J. Skehel, P.M. Bayley, E.B. Brown, S.R. Martin, M.D. Waterfield, J.M. White, I.A. Wilson and D.C. Wiley Changes in the conformation of influenza virus haemagglutinin at the pH optimum of virus mediated membrane fusion Proc. Nat.Acad.Sci.USA 79: 968 (1982)CrossRefGoogle Scholar
  36. 36.
    J. White, K. Matlin and A. Helenius Cell fusion by Semliki Forest, influenza and vesicular stomatitis viruses. J.Cell Biology 89: 674 (1981)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1984

Authors and Affiliations

  • J. S. Oxford
    • 1
  1. 1.Viral Products DivisionNational Institute for Biological Standards and ControlLondon NW6UK

Personalised recommendations